Graft-versus-host disease (GvHD) remains a major cause of morbidity and non-relapse mortality after allogeneic hematopoietic cell transplantation. Building on prior evidence implicating mitochondrial DNA (mtDNA) variation in myelodysplastic neoplasms (MDS), we investigated the prognostic impact of recipient and donor m...
Shahram Arsang-Jang, Tao Zhang, M. Rafati et al.· Journal of Hematology & Onco...· 0 citations
Germline DDX41 variants are a recognized cause of adult myelodysplastic neoplasms (MDS), characterized by distinct biological features and favorable prognosis. The independent effect of DDX41 status on outcomes after allogeneic transplantation, the role of conditioning intensity, and treatment-related toxicity risk rem...
N. Gagelmann, Christopher R. Reilly, Archana Sasi et al.· Blood· 0 citations
It is suggested that PTCy narrows outcome differences across donor types, shifting donor selection from rigid hierarchies and supporting timely HCT using the best available donor.
Y. Aljawai, Masumi Ueda Oshima, Varuna Astha et al.· Blood Advances· 0 citations
Among adult ACCESS recipients treated on a uniform young-donor PBSC/PTCy platform, short-term outcomes with predominantly 6/8 MMUD transplantation were encouraging and should not be interpreted as establishing equivalence with 7/8 MMUD transplantation.
A. J. Jimenez Jimenez, Joseph Stanek, Brent Logan et al.· Blood Advances· 0 citations
MMUD with PTCy-based GVHD prophylaxis and RIC/NMA conditioning was safe and effective to facilitate HCT and outcomes were similar in the expansion cohort that enrolled from a greater number of centers.
Brian C. Shaffer, M. A. Al Malki, Antonio M. Jimenez et al.· American journal of hematolo...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.